Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
The patient had a high-grade DCIS with necrosis, but a 0.9 DCSionRT score
Answer from: Radiation Oncologist at Community Practice
For now, I have been only omitting/discussing omission if both, clinical path and molecular test are concordant.
Sign In
or
Register
to read more
21306
Related Questions
How do you advise women to manage wound care for breast brachytherapy needle sites for long term cosmetic outcomes?
Is it appropriate to consider ultra-hypofractionation for phyllodes tumors of the breast when adjuvant radiotherapy is indicated?
How do you approach reirradiation in a patient who underwent breast-conserving surgery for recurrent breast cancer after initial lumpectomy and APBI?
In a young woman with large invasive breast carcinoma (case: pT3, lobular) s/p skin sparing mastectomy with positive anterior margin, what is the practical role for re-excision with or without PMRT?
When using surface image-guidance for breast radiation, how do you accommodate for changes in anatomy?
Is DCISionRT appropriate for multifocal DCIS?
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
What are your top takeaways in Medical Oncology from SABCS 2024?